Skip to main content

Advertisement

Table 1 Comparison of baseline characteristics between PDAC patients in the OPD and LPD groups

From: Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis

Characteristic Original cohort P Matched cohort P
OPD group LPD group OPD group LPD group
Total (cases) 230 79   93 55  
Age [years, median (IQR)] 64.0 (57.0–69.3) 64.0 (56.0–70.0) 0.817 64.0 (59.0–70.5) 63.0 (54.0–69.0) 0.337
Gender [cases (%)]    0.027    0.959
 Male 140 (60.9) 59 (74.7)   68 (73.1) 40 (72.7)  
 Female 90 (39.1) 20 (25.3)   25 (26.9) 15 (27.3)  
BMI [kg/m2, median (IQR)] 22.5 (20.5–24.2) 23.2 (20.7–25.3) 0.100 22.3 (20.3–23.9) 23.0 (20.7–25.2) 0.107
ASA score [cases (%)]    0.059    0.149
 1 43 (18.7) 6 (7.6)   18 (19.4) 5 (9.1)  
 2 177 (77.0) 68 (86.1)   73 (78.5) 47 (85.5)  
 3 10 (4.3) 5 (6.3)   2 (2.2) 3 (5.5)  
Charlson comorbidity index [cases (%)]    0.324    0.356
 0 144 (62.6) 44 (55.7)   58 (62.4) 31 (56.4)  
 1 64 (27.8) 29 (36.7)   28 (30.1) 22 (40.0)  
 ≥ 2 22 (9.6) 6 (7.6)   7 (7.5) 2 (3.6)  
Year of operation [cases (%)]    0.256    0.447
 2013–2015 114 (49.6) 45 (57.0)   55 (59.1) 29 (52.7)  
 2016–2017 116 (50.4) 34 (43.0)   38 (40.9) 26 (47.3)  
Tumor differentiation [cases (%)]    0.006    0.421
 Well-moderate 82 (35.7) 42 (53.2)   41 (44.1) 28 (50.9)  
 Poor 148 (64.3) 37 (46.8)   52 (55.9) 27 (49.1)  
Nerve invasion [cases (%)]    < 0.001    0.131
 Yes 203 (88.3) 44 (55.7)   73 (78.5) 37 (67.3)  
 No 27 (11.7) 35 (44.3)   20 (21.5) 18 (32.7)  
T stage [cases (%)]    0.001    0.835
 1 61 (26.5) 12 (15.2)   15 (16.1) 10 (18.2)  
 2 158 (68.7) 54 (68.4)   73 (78.5) 41 (74.5)  
 3 11 (4.8) 13 (16.5)   5 (5.4) 4 (7.3)  
N stage [cases (%)]    0.942    0.886
 0 123 (53.5) 44 (55.7)   50 (53.8) 32 (58.2)  
 1 86 (37.4) 28 (35.4)   35 (37.6) 19 (34.5)  
 2 21 (9.1) 7 (8.9)   8 (8.6) 4 (7.3)  
AJCC TNM stage [cases (%)]    0.794    0.831
 I 117 (50.9) 37 (46.8)   46 (49.5) 30 (54.5)  
 II 92 (40.0) 35 (44.3)   39 (41.9) 21 (38.2)  
 III 21 (9.1) 7 (8.9)   8 (8.6) 4 (7.3)  
Adjuvant treatment [cases (%)]    < 0.001    0.701
 Yes 162 (70.4) 31 (39.2)   47 (50.5) 26 (47.3)  
 No 68 (29.6) 48 (60.8)   46 (49.5) 29 (52.7)  
  1. PDAC pancreatic ductal adenocarcinoma, OPD open pancreaticoduodenectomy, LPD laparoscopic pancreaticoduodenectomy, IQR interquartile range, BMI body mass index, ASA American Society of Anesthesiologists score, AJCC American Joint Committee on Cancer. The 8th edition of AJCC TNM staging system was used